Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback